Background . Acquired resistance to imatinib is frequently caused by secondary KIT mutations. We have investigated the effects of imatinib in mice with human gastrointestinal stromal tumour (GIST) xenograft which harbours a primary exon 11 deletion mutation and a secondary imatinib resistance mutation D816H in exon 17. Such mutations are commonly present in imatinib-resistant GIST in humans. Material and methods . The mice were randomly allocated to receive imatinib either continuously or intermittently. Dynamic 18 F-FDG PET was performed and blood volume fraction ( v B ), rate transfer constants ( k 1 , k 2 , k 3 ) and metabolic rate of 18 F-FDG ( MR FDG ) were computed using a three-compartment model. Tumours were evaluated for the mitotic rate and the expression of HIF-1 α , caspase-3 and glucose transporters (GLUTs). Results. Both intermittent and continuous imatinib delayed tumour growth signifi cantly compared to controls, signifi cantly in favour of the latter. k 1 (representing perfusion, vascular permeability and binding of 18 F-FDG to the GLUTs) was signifi cantly higher in the intermittent group compared to the continuous group, as was tumour GLUT-3 expression. k 3 (representing internalisation of 18 F-FDG to the cells) and MR FDG were signifi cantly lower. Conclusion. Imatinib delays GIST xenograft growth despite the presence of the D816H resistance mutation. The schedule of imatinib administration may infl uence tumour glucose uptake rate and metabolic rate.
Gastrointestinal stromal tumour (GIST) is the most common sarcoma of the digestive tract [1] . Approximately 95% of GISTs express KIT, the receptor for the stem cell factor [2] . KIT mutations frequently result in KIT phosphorylation and constitutive activation. In a few GISTs (5 -10%) a mutation is found in the gene encoding the platelet-derived growth factor receptor alpha ( PDGFRA ). Both KIT and PDG-FRA receptors are tyrosine kinases and key players in GIST tumourigenesis [3] . By the introduction of the tyrosine kinase inhibitor (TKI) imatinib, a selective inhibitor of KIT, PDGFRA and a few other kinases, a new era in the management of GIST began [4, 5] . Most patients with advanced GIST respond to imatinib, the standard fi rst-line treatment, but the majority eventually progress with the median time to imatinib resistance being approximately two years [5] . In acquired imatinib resistance secondary mutations in KIT exons 13 and 17 are common resulting in a kinase conformation that prohibits imatinib from binding to the kinase [6] .
A metabolic response to imatinib in GIST may be observed early with 2-deoxy-2-[ 18 F]fl uoro-Dglucose ( 18 F-FDG) positron emission tomography (PET) [4] , sometimes even within a few hours after starting imatinib [7, 8] . Dynamic 18 F-FDG PET enables assessment of tissue uptake of the tracer in space and time following injection and may offer valuable information about tumour vascularisation and its metabolic characteristics [9] .
Human tumour xenografts are useful for evaluating novel therapeutic agents, since tumour vascular and stromal components cannot be addressed in vitro . The GIST human xenograft model AHAX [10] originates from a patient with a clinically imatinib-resistant GIST harbouring a primary KIT exon 11 mutation (sensitive to imatinib) and a secondary KIT exon 17 mutation (likely treatment-induced mutation). Since KIT exon 11 is the most common site of mutation in primary GIST and KIT exon 17 is the most frequent site of a secondary resistance mutation [11] , this model refl ects the most common clinical scenario in imatinib-resistant GIST.
Imatinib, administered usually continuously at a dose of 400 mg/day, is generally well tolerated and despite prior tumour progression during fi rst-line imatinib it is often considered as the last-line palliative systemic treatment for patients with advanced GIST [12] . This practice is, however, controversial in the absence of other than anecdotal supportive clinical experiences. A randomised clinical trial is currently comparing imatinib plus the best supportive care to the latter alone as palliative treatment of advanced GIST (ClinicalTrials.gov identifi er NCT1151852). Somewhat unexpectedly withdrawal of imatinib in responding patients and reinstitution of imatinib at the time of metastatic progression, did not affect survival in a large randomised clinical trial [13, 14] .
The aim of the present study was to evaluate the potential benefi ts of continuous and intermittent imatinib administration in an experimental human GIST xenograft model harbouring imatinib resistance mutation. This was evaluated by tumour growth measurements and assessment of tumour metabolic activity (with dynamic 18 F-FDG PET), mitotic rate, and expression of HIF-1 α , caspase-3 and GLUTs.
Material and methods

Animals and xenografts
Human GIST AHAX xenografts with a mutation in KIT exon 11 (c.1673_1687del, p.Lys558_Glu562-del) and KIT exon 17 (c.2446G Ͼ C, p.Asp816His) [10] were established by subcutaneous implantation of tumour tissue fragments ( ~ 2 ϫ 2 ϫ 2 mm 3 ) bilaterally into NCR athymic mice. The mice were kept under specifi c pathogen-free conditions at a constant temperature (22 -24 ° C) and humidity (55 -60%), and were given sterilised food and tap water ad libitum.
Six weeks after implantation 37 mice were randomly allocated into a control group (n ϭ 12) or to one of two imatinib treatment groups, where imatinib was administrated either continuously (n ϭ 13) or intermittently (n ϭ 12, one week on and one week off). 
Tumour volume measurements
Tumour size was measured by a caliper twice weekly from the date of implantation. Tumour volume was calculated using the modifi ed ellipsoid formula [15] , where the volume V (mm 3 ) ϭ ( π /6) ϫ a (mm) ϫ b 2 (mm 2 ), a and b being the longest and the perpendicular tumour diameters, respectively. The measurements were normalised to individual pre-treatment (day 0) tumour volumes. Estimated tumour volume doubling time was calculated using linear regression on lntransformed normalised tumour volumes.
Imatinib administration
Imatinib (Glivec ® , Novartis Pharma GmbH, Basel, Switzerland) was dissolved in distilled water and given by oral gavage: either 100 mg/kg once daily (the continuous treatment group) or in two-week cycles, with imatinib given daily for seven days followed by placebo (water) for seven days (the intermittent treatment group). The control group received water only by oral gavage. The duration of the experiment was 91 days.
Dynamic 18 F-FDG PET imaging
Four mice from each of the three groups underwent dynamic 18 F-FDG PET one day prior to sacrifi ce, using a small animal PET scanner (microPET Focus 120, Siemens Medical Solutions, Erlangen, Germany). Following overnight fasting the mice were anesthetised and given an i.v. bolus injection of 7 -10 MBq 18 F-FDG (GE Healthcare AS, Oslo, Norway) diluted in heparinised saline [7] . Acquisition of list-mode data started prior to 18 F-FDG injection and lasted for 50 minutes post-injection. The dynamic PET images were reconstructed using OSEM-MAP [16, 17] producing images with a voxel size of 0.87 ϫ 0.87 ϫ 0.80 mm 3 . The reconstructed time frames were 10 seconds during the initial 1.5 minutes followed by reduced temporal resolution for the remaining frames. Kinetic modeling of the DICOM-images was performed using in-house written IDL-programs (Interactive Data Language, v6.2, Research Systems Inc., Boulder, CO, USA). Briefl y, the mean time activity curves (TACs) for each tumour were calculated and normalised to individual arterial input functions (AIFs) to account for differences in the injected 18 F-FDG activity between the animals [9] .
A three-compartment model consisting of a blood compartment and two sequential tissue compartments was used to evaluate the 18 F-FDG kinetics. The concentration in tissue ( C T ) is assumed to be separated into a free (non-metabolised) and a bound (metabolised) compartment with tracer concentrations of C F and C B , respectively (Figure 1 ). The exchange of 18 F-FDG between the two tissue compartments is described by the rate constants k 1 , k 2 , k 3 , and k 4 [min Ϫ1 ], where k 1 includes perfusion, vascular permeability and the binding of 18 F-FDG to the GLUT receptors, k 2 the clearance of 18 F-FDG back into the blood, k 3 the cellular internalisation, and k 4 the cellular externalisation. The kinetic parameters were estimated by fi tting the TAC to this model and non-linear least squares minimisation. k 4 was assumed to be low, and was set to zero in the calculations. The blood volume fraction ( v B ) was estimated as described previously [18] . The metabolic rate of 18 F-FDG ( MR FDG ) was defi ned as (
. The fi t between the measured TACs and the curves obtained from modeling were evaluated by calculating correction coeffi cients ( r 2 ) for each tumour voxel.
Histopathology and immunohistochemistry
At the end of the experiment the mice were sacrifi ced by neck dislocation and tumour sites were matched with the in vivo imaging slices. The xenografts were excised and divided in two; one half was snap-frozen in liquid nitrogen and stored at Ϫ 80 ° C, while the second half was formalin-fi xed and paraffi n-embedded.
The paraffi n-embedded sections were stained using a standard method (Dako EnVisionTM ϩ System, Peroxidase (DAB) (K4011, Dako, Glostrup, Denmark) and a Dako Autostainer). The primary antibodies, dilutions, pH retrieval solution and the positive controls are listed in Table I . The proportion of positively staining tumour cells was assessed semiquantitatively as absent (0, no immunostaining), slight (1, Ͻ 10% of tumour cells were stained), moderate (2, 10 -50% of cells showed staining), or strong (3, Ͼ 50% of cells were stained). The intensity of staining was recorded as absent (0), weak (1), moderate (2) or strong (3). A staining score was obtained by multiplying these two values. The mitotic index was counted per 20 high power fi elds (HPFs) using a Leica DM2500 microscope (Leica Microsystems CMS, Germany) with an objective ϫ 40 giving an area of 0.31 mm 2 for a single HPF.
KIT and PDGFRA mutation analysis
Genomic DNA was extracted from 10 AHAX xenografts. Thirty nanograms of DNA was amplifi ed using Phusion ® Hot Start DNA polymerase and Phusion GC buffer (Finnzymes, Espoo, Finland). The thermal cycling conditions were DNA denaturation at 98 ° C for 30 seconds, fi ve cycles at 98 ° C for 10 seconds, 65 ° C for 15 seconds and 72 ° C for 10 seconds, followed by 35 similar cycles where the annealing temperature was reduced to 60 ° C. Final extension was allowed at 72 ° C for 1 minute (The forward and reverse PCR primer pairs used can be provided upon request). The sequencing reactions were performed in two directions using the BigDye ® Terminator v1.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, CA, USA). The sequencing products were run on an automatic capillary sequencer (3130xl Genetic Analyzer, Life Technologies, Paisley, UK).
Statistical analysis
Statistical analyses were performed using Excel ® (Microsoft Corporation, Redmond, WA, USA) and SPSS version 18.0 (SPSS Science, Chicago, IL, USA). Non-Gaussian distributions were compared using the non-parametric Mann-Whitney U-test. Two-sided t-test was used to compare the fi rst order least-square linear regression estimated tumour doubling times. Signifi cance was set to 5%.
Results
Tumour growth
Tumour growth was observed in 70 (95%) of the 74 implants in the 37 mice. One mouse was sacrifi ced prematurely because of oesophageal perforation and 
Dynamic 18 F-FDG PET
18 F-FDG PET of the treated animals was performed after 88 days of treatment, at a time point where both treatment groups were receiving imatinib. Figure 3A shows a series of 18 F-FDG PET images demonstrating tracer uptake in a fl ank tumour in the continuous imatinib group. The TACs from the tumours treated with intermittent imatinib showed higher uptake and reached a plateau earlier after tracer injection as compared to the tumours treated with continuous imatinib (25 minutes vs. 30 minutes, respectively). The median area under the normalised TAC curve was 20% higher for the intermittent group, albeit not signifi cantly different (p ϭ 0.08) (data not shown). TACs of two voxels located at different sites within a continuous imatinib-treated xenograft are shown in Figure 3B . Using kinetic modeling, the TAC of the voxels were separated into free (not metabolised) and bound (metabolised) components. The goodness of fi t between the measured TACs and the uptake curves obtained from modeling ranged from 0.91 to 0.98 with no signifi cant differences between the two treatment groups. Mean k 1 , k 2 , k 3 , MR FDG and v B for both treatment groups are summarised in Table II . Signifi cant differences were found for the kinetic parameters k 1 , k 3 and MR FDG . The infl ux k 1 parameter was 32% higher in the intermittent group (p ϭ 0.01), while k 3 and MR FDG were 95% (p ϭ 0.01) and 50% (p ϭ 0.03) higher in the continuous treatment group, respectively. No signifi cant correlations were found between the tumour volumes and the tumour pharmacokinetic parameters.
Tumour histology and immunohistochemistry
Microscopic examination of the haematoxylin stained tumour sections revealed no differences in tumour morphology between the three groups. However, the mitotic index was signifi cantly higher in the control group (median; 13 mitoses/20 HPFs) as compared to the continuous and the intermittent group (both medians 4/20 HPFs, p ϭ 0.02). The cytoplasmic GLUT-1 expression was signifi cantly higher in the control group as compared to the intermittent group (median score 9 vs. 6; p ϭ 0.023) and the continuous group (median score 6; p ϭ 0.009). Both treatment groups had a signifi cantly higher expression of cytoplasmic GLUT-2 (both median scores 9) than the control group (median score 3; p Ͻ 0.001). The expression of both the cytoplasmic and the membranous form of GLUT-3 were signifi cantly higher (p Ͻ 0.001) in xenografts treated with intermittent differences between the three groups with respect to HIF-1 α or caspase-3 expression (data not shown).
KIT and PDGFRA mutations
Ten xenografts (continuous group, 4; intermittent group, 3; control group, 3) were analysed for KIT and PDGFRA mutations to investigate tumour mutation status at the end of the experiment. Sequencing confi rmed that all xenografts had maintained the original mutation in KIT exon 11 (c.1673_1687del, p.Lys558_Glu562del ) and in KIT exon 17 (c.2446G Ͼ C, p.Asp816His). No further mutations were detected in KIT exons 9, 14 or 17, or in PDGFRA exons 12, 14 or 18.
Discussion
We explored the effects of imatinib administered either intermittently or continuously in a human Figure 1 ; MR FDG , the metabolic rate of 18 F-FDG; v B , the estimated blood volume. * p for the difference between the intermittent and continuous imatinib groups.
imatinib (median score 3 and 3, respectively) as compared to xenografts treated with continuous imatinib (median score 0 and 0, respectively). There were no showed no benefi ts during the 91-day observation period. The AHAX xenograft model of human GIST has proven useful for studying 18 F-FDG uptake responses to TKIs [7] . In the current study we found differences in the dynamic 18 F-FDG uptake characteristics between the intermittent and the continuous treatment groups imaged while the mice were on imatinib. The TAC amplitude was higher in the intermittent group indicating either increased perfusion and/or increased metabolism compared to the continuous group. The tumour metabolic rate ( MR FDG ), in turn, was higher in the continuous group, whereas k 1 was higher and k 3 lower in the intermittent group as compared to the continuous group suggesting presence of more perfusion, vascular permeability or vascular damage (high fl ow, leaky vessels) in the intermittent group [20] . Lack of correlations between tumour volumes and kinetic parameters indicate that tumour size could not explain the observed differences in FDG uptake. Taken together, these fi ndings suggest that the schedule of imatinib administration infl uences tumour glucose uptake and metabolic rate. This observation should, however, be interpreted with some caution, since only four mice from each group underwent dynamic PET and the tumours showed heterogeneity in the PET parameters.
The GLUTs play a central role in the accumulation of 18 F-FDG within tumour cells. GLUT-1 is present in most cell types and is a key factor in glucose uptake, but different cancers express different GLUTs [21, 22] . We found a difference in GLUT-3 expression between the two treatment groups. GLUT-3 is expressed in neurons and was originally designated as the neuronal GLUT. GISTs may show both muscle and neuronal differentiation and GLUT-3 expression may in part be related to rapid 18 F-FDG uptake in GISTs [23] . Imatinib induces GLUT translocation from the plasma membrane to the cytosol via endocytosis [24, 25] . In line with this, we found higher cytoplamic GLUT-2 expression in both imatinib groups compared to the control group.
In conclusion, the present study suggests that continuation of imatinib treatment may still benefi t some GIST patients despite presence of an imatinib resistance mutation, such as D816H. In this setting, imatinib may slow down tumour progression, possibly by inhibiting the imatinib-sensitive primary mutation. Both continuous imatinib administration and the alternating one week on -one week off administration slowed down tumour progression, but the tumour growth was signifi cantly more rapid with the alternating scheme. We found differences in 18 F-FDG uptake kinetics and tumour 18 F-FDG metabolic rate between the continuous and the intermittent imatinib GIST xenograft harbouring the D816H mutation, which is a mutation considered to cause clinical imatinib resistance in GIST patients. The results show that the tumours do not regress either with intermittent or continuous imatinib, but, notably, they grow at a substantially slower rate than untreated tumours. This fi nding suggests that GISTs with a KIT 11 deletion mutation coupled with a D816H substitution mutation are not entirely imatinib-resistant. From a clinical point of view this is potentially an important observation, since the KIT exon 11 deletion mutation is the most common mutation in GIST, and exon 17 point mutations are the most frequent mutations considered to confer imatinib resistance. In clinical practice, imatinib administration is often discontinued when advanced GIST stops to respond to imatinib, and alternative treatments such as sunitinib or other TKIs are instituted. Anecdotal clinical experience suggests that reinstitution of imatinib after failure of the second-or third-line TKI treatments may still slow down GIST progression compared to no systemic treatment. Although fi rm clinical evidence is lacking, reinstitution of imatinib may still be advantageous as the last-line palliative care [12] .
The reason for imatinib benefi t in the presence of D816H remains hypothetical. The KIT exon 11 deletion mutation, unlike the D816H mutation, continues to be sensitive to imatinib, which may results in a less active KIT kinase in the presence of imatinib as compared to a kinase where both mutations are uninhibited. If this hypothesis is correct, the present fi ndings may have relevance to many GISTs with an imatinibsensitive primary mutation and an imatinib-insensitive secondary mutation. The original primary mutation is virtually always present in GISTs that contain a secondary resistance mutation [11] . Of note, more than one secondary mutation are commonly found in tumours that grow during imatinib treatment, sometimes even within the same metastasis [19] . Our fi ndings may thus lend support to rechallenge with imatinib, even in cases when multiple secondary resistance mutations are present, provided that the primary mutation is imatinib-sensitive.
The French Sarcoma Group investigated in the randomised BRF14 trial the effect of interrupting imatinib treatment at after either one, three or fi ve years of treatment in patients with advanced GIST who continued to respond to imatinib. Interruption of imatinib resulted in rapid GIST progression in the majority of patients, but almost all patients responded to imatinib reinstitution. No overall survival difference was seen between the interruption and the continuation groups, regardless of the timing of imatinib interruption [13, 14] . Rapid cycling of imatinib administration (one week on, one week off) has not been tested in clinical trials, but the present result administration groups, but their clinical signifi cance remains unknown.
